Genetic Modifiers of Age at Onset in Carriers of the G206A Mutation in PSEN1 With Familial Alzheimer Disease Among Caribbean Hispanics by Lee, Joseph H. et al.
Copyright 2015 American Medical Association. All rights reserved.
Genetic Modifiers of Age at Onset in Carriers
of the G206AMutation in PSEN1With Familial
Alzheimer Disease Among Caribbean Hispanics
Joseph H. Lee, DrPH; Rong Cheng, PhD; Badri Vardarajan, PhD; Rafael Lantigua, MD; Dolly Reyes-Dumeyer, BS;
Ward Ortmann, PhD; Robert R. Graham, PhD; Tushar Bhangale, PhD; TimothyW. Behrens, MD;
Martin Medrano, MD; Ivonne Z. Jiménez-Velázquez, MD; RichardMayeux, MD, MSc
IMPORTANCE The present study identified potential genetic modifiers that may delay or
accelerate age at onset of familial Alzheimer disease (AD) by examining age at onset in PSEN1
mutation carrier families, and further investigation of these modifiers may provide insight
into the pathobiology of AD and potential therapeutic measures.
OBJECTIVE To identify genetic variants that modify age at onset of AD.
DESIGN, SETTING, AND PARTICIPANTS Using a subset of Caribbean Hispanic families that carry
the PSEN1 p.G206Amutation, we performed a 2-stage genome study. Themutation carrier
families from an ongoing genetic study served as a discovery set, and the cohort of those with
LOAD served as a confirmation set. To identify candidate loci, we performed linkage analysis
using 5 p.G206A carrier families (n = 56), and we also performedwhole-exome association
analysis using 31 p.G206A carriers from 26 families. To confirm the genetic modifiers
identified from the p.G206A carrier families, we analyzed the GWAS data for 2888 elderly
individuals with LOAD. All study participants were Caribbean Hispanics.
MAIN OUTCOMES ANDMEASURES Age at onset of AD.
RESULTS Linkage analysis of AD identified the strongest linkage support at 4q35 (LOD
[logarithm of odds] score, 3.69), and the GWAS of age at onset identified variants on 1p13.1,
2q13, 4q25, and 17p11. In the confirmation stage, genewise analysis identified SNX25, PDLIM3,
and 3 SH3 domain genes (SORBS2, SH3RF3, and NPHP1) to be significantly associated with
LOAD. Subsequent allelic association analysis confirmed SNX25, PDLIM3, and SORBS2 as
genetic modifiers of age at onset of EOAD and LOAD and providedmodest support for
SH3RF3 and NPHP1.
CONCLUSIONS AND RELEVANCE Our 2-stage analysis revealed that SNX25, PDLIM3, and
SORBS2may serve as genetic modifiers of age at onset in both EOAD and LOAD.
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I n 2001, we identified a p.Gly206Ala (g.44636G>C) variantin PSEN1 (OMIM 104311) in members of 8 Caribbean His-panic familieswith early-onset Alzheimer disease (EOAD)
fromPuerto Rico.1 Subsequently, Arnold and colleagues2 also
reported this mutation in additional individuals from Puerto
Rico but not in other ethnic groups. The mean age at onset
among mutation carriers was 55.6 years but was highly vari-
able within families, ranging from 22 to 77 years. The pres-
enceof neither anAPOE ε4 allele nor any antecedent environ-
mental, health-related, or social factors could explain the
differences in the age at onset amongmutation carriers, lead-
ing us to suspect that other geneswere involved in determin-
ing when, but not whether, p.G206A carriers develop AD.
Late-onsetdiseases, includingAD,3,4Huntingtondisease,5-7
andParkinsondisease,8,9 havebeen studied for geneticmodi-
fiers of age at onset in the presence of amajor genetic risk fac-
tor (ie, pathogenicmutation), recognizing that there are likely
geneticvariants that contribute tophenotypic expression.Few
studies10,11 have reported gene-gene interaction in AD be-
cause different individuals are likely to carry different ge-
netic risk factors. Since there are approximately 185 known
PSEN1variants associatedwithADand thesevariants are rare,
most studies will not have sufficient statistical power.12
We conducted a 2-stage study on a set of families multi-
ply affectedbyADwithat least onecarrier of thep.G206Avari-
ant in the PSEN1 gene to identify genetic modifiers of age at
onset amongcarriers. In thediscovery stage,weused thesege-
netically homogeneous families inwhichnearly all carriers of
thePSEN1mutationhadp.G206A.Usingasubsetofcarrier fam-
ilymembers,weappliedbothgenome-wide linkageandexome
sequencinganalyses (eFigure 1 in theSupplement). In the con-
firmation stage, we examined allelic association between age
at onset and variants in the same candidate genes in a cohort
of thesameancestrywith late-onsetAD(LOAD).Wereport that
variants in SNX25, PDLIM3, SORBS2, and SH3RF3were asso-
ciatedwith variation in age at onset in families with a copy of
PSEN1p.G206Amutationand inLOAD. Inaddition, at leastone




Weconducted a 2-stage study to identify geneticmodifiers of
age at onset of AD using multiple sets of data in which some
were family based and others comprised unrelated individu-
als (eFigure 1 in the Supplement). The study protocol was ap-
provedby theColumbiaUniversity InstitutionalReviewBoard,
andwritten informed consentwas provided by all the partici-
pants. Using 56 family members from 5 families with EOAD
with the PSEN1 p.G206A mutation, we performed linkage
analysis to identify candidate loci. These families represent a
subset ofPSEN1 carrier familieswith awide rangeof age at on-
set amongaffected individuals.Familymembers resided in the
United States, Puerto Rico, Dominican Republic, and coun-
tries in South America. Although these families were se-
lectedbecausemultiplemembershadEOAD (age at onset, ≤65
years),manyof these families had some familymemberswho
had LOAD (age at onset, >65 years). In addition, we per-
formed an exome sequencing experiment and found 31 carri-
ers from 26 families who hadmultiple affectedmembers and
at least 2 who had the PSEN1 p.G206A mutation. Nine of the
31 individualswerealso included in the linkageanalysis.Given
the small sample size of carrier families examined, the main
goal of this discovery stage is to prioritize candidate loci.13
Confirmation Cohort
For the LOAD validation experiment, we examined 2888
Caribbean Hispanic elderly people who were noncarriers of
the PSEN1 p.G206A mutation and were included in separate




single-nucleotide polymorphism (SNP) chips (Illumina Inc).
This SNP chipwas designed to obtain information for linkage
signals. Before analysis, we conducted the standard quality
control checks, including checking of the reported family re-
lationshipsusing the softwarePREST,14Hardy-Weinberg equi-
librium, and genotyping rate. The details of the quality con-
trol procedures are presented elsewhere.15,16
Genome-wide Linkage Analysis
To identify regions thatmaycontainvariants that couldmodify
ageatonset, linkageanalyseswereperformedusingthe6Klink-
age panel SNP data from 56 individuals in 5 families. We ex-
aminedAD and age at onset as phenotypes.We reasoned that
variants that lead to early age at onset are likely to increase the
risk of AD, whereas variants that delay age at onset may re-
duce the risk. For AD phenotype, single-point analysis as-
sumedan autosomal dominantmodeof inheritance andused
the affecteds-only approach 17 inPSEUDOMARKER.18 For age-
at-onset phenotype, we used age at onset for affected indi-
viduals and age at last examination for unaffected individu-
als. We then applied the multipoint variance component
method to identify candidate loci as implemented in SOLAR
statistical software.19 This variance componentmodelwas ad-
justed for sex, APOE ε4, and AD status.
To prioritize candidate genes under the linkage peak at
4q35.1, thetop linkagepeak,wescreenedcandidategenesusing
CANDID, version 1.1.20 Higher weights were given to loga-
rithm of odds (LOD) score (weight, 2) and conservation
(weight, 2) comparedwith literature (which included the key-
words Alzheimer disease, neurodegeneration, early onset, and
beta amyloid) (weight, 1) and gene expression (weight, 1).
Exome Sequencing
Whole-exome capture libraries were constructed from DNA
from whole blood of the samples after sample shearing, end
repair, phosphorylation, and ligation to bar-coded sequenc-
ing adaptors (eFigure 2 in the Supplement). The ligated DNA
wassubjectedtoexonichybridcaptureusingtheNimbleexome
capturearray(http://www.nimblegen.com/seqcapez/).Samples
weremultiplexed and sequenced onmultiple Illumina HiSeq
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flow cells for a mean target exome coverage of 80× to gener-
ate paired-end reads of 90 base pairs.
ReadMapping, Variant Calling, and Downstream
Bioinformatics Analyses
Prealignmentquality control of the readdata to identify failed
runs and laneswasperformedusing theRBioConductorpack-
age: ShortRead (http://www.bioconductor.org/). Sequence
alignmentwas performedusing the aligner BWA. Polymerase
chain reaction duplicates (reads) were removed using Picard
tools. Base quality recalibration and realignment around in-
delswereperformedusing theGenomeAnalysisToolkit (https:
//www.broadinstitute.org/gatk/).Multisample variant calling
and quality control of the call were then performed using the
Genome Analysis Toolkit. On the basis of the hypothesis that
themutationunderlying this rarer formofEOADwasnotpres-
ent in the general population, SNPs identified in the 1000Hu-
man Genomes (HG) project (version 2010-11; http://www
.1000genomes.org) or in dbSNP (build 134; http://www.ncbi
.nlm.nih.gov/projects/SNP) were removed. Exonic coding
variants were identified and annotated by ANNOVAR (http:
//annovar.openbioinformatics.org/en/latest/).Non-exonic and
synonymous variantswere filtered from the variant list using
predictions fromSIFT (Sorting Intolerant FromTolerant) soft-
ware, version 4.0 (http://sift.jcvi.org).
Genome-wide Association Analysis
Using 31 individuals with exome sequencing data, we exam-
ined candidate genes under the top linkage peak and the rest
of the exome by applying a mixed linear model adjusting for
sex, APOE genotype, affection status, and kinship coeffi-
cient. The kinship coefficient matrix using the R functions21
was included in the model to take into account relatedness
among family members.
Replication Using the LOADHispanic GWASData Set:
Genewise Analysis
To determine whether candidate genes identified from the
EOADcohortwere similarly associatedwith age at onset ofAD
in the LOAD cohort of the same ethnic background, we per-
formedgenewiseassociationanalysisusing family-basedSKAT
software (FAMSKAT),22 adjusting for sex,ADstatus, andAPOE
ε4. This approach was necessary because (1) multiple vari-
ants within one gene had modest effects on age at onset and
(2)mostof thevariants identified fromexomesequencingwere
absent in the GWAS data of Caribbean Hispanics.
Imputation of the LOADHispanic GWASData Set
Imputations of 5 genes (SNX25, PDLIM3, SORBS2, SH3RF3,
NPHP1) were performed based on cosmopolitan phased hap-
lotypes of 1000 HG, version 2010–11 (data freeze, 2012-03-04
haplotypes; http://csg.sph.umich.edu//abecasis/MaCH
/download/1000G.2012-03-14.html). PLINK,version 1.07 (http:
//pngu.mgh.harvard.edu/~purcell/plink/) was used for impu-
tation.Before imputing, anumberof filterswere implemented
in theHispanicGWASgenotypicdatabyremovingmarkers that
had a minor allele frequency less than 1%, a Hardy-Weinberg
equilibrium P <10−6, Hispanic GWAS SNP alleles mismatched
with those of 1000HGproject and not present in the 1000HG
panel, and flipping of any SNP when appropriate to the for-
ward strand. A total of 348 924 SNPs for 2 regions of chromo-
some 2 (175 288 SNPs, approximately 14 Mbp) and chromo-
some 4 (173 636 SNPs, approximately 10Mbp) were imputed.
For single-variant and single-trait association with imputed
genotypes, 2 additional filters were implemented: minor al-
lele frequencygreater than1%andan informationscoregreater
than 0.8 (a quality score from the imputation), which re-
duced the analysis to 2636 variants within the 3 genes.
Association Analysis andMeta-analysis
We applied the same multivariate linear mixed model that
adjusted for sex, AD status, and APOE ε421 as above to test
the allelic association between age at onset and variants in
LOAD. We then conducted a meta-analysis to assess whether
the SNPs in the 3 candidate genes were significantly associ-
ated with the LOAD GWAS data sets. For this purpose, we
estimated the meta-analysis of P values from 4 studies as
implemented in theMETAL(http://csg.sph.umich.edu//abecasis
/metal/), which estimates a single summary P value across 3
data sets. An overall z statistic and P value were calculated
while taking into account the number of individuals exam-
ined in each study.
Results
Study Participants
Table 1 details the 3 sets of Caribbean Hispanics investigated:
(1) families who have multiple affected members and at least
one carrying the PSEN1 p.G206A mutation were analyzed
using linkage analysis; (2) carriers of the PSEN1 p.G206A
mutation from families who have multiple affected members
were analyzed using exome sequencing; and (3) 3 confirma-
tory GWAS data sets of Caribbean Hispanics primarily com-
posed of LOAD were studied,15,23 which were analyzed using
a linear mixed model to assess allelic association. All 3 data
sets had both family members and unrelated individuals, and
appropriate statistical methods were applied to account for
nonindependence.
Linkage Analysis Set
Of 56 family members included in the linkage analysis, 21
(37.5%)were affected, and 32 (57.1%)were unaffected. A total
of 37 (66.1%) of the family members were women, the mean
(SD) age at onset of AD was 57.2 (7.0) years (range, 43.0-73.0
years), andthemeaneducational levelwas10.0years.Theover-
all allele frequency of APOE ε4 was 20.5%.
Exome Sequencing Set
Of 31 PSEN1 p.G206Amutation carriers from 26 families who
were included in theexomesequencingexperiment, 26 (83.9%)
of themutation carriers had been clinically diagnosed as hav-
ing AD. The other personswere unaffected carriers. Nineteen
participants (61.3%)werewomen, themean (SD) agewas 57.9
(9.9) years (range, 44.0-77.0 years), and the mean educa-
tional level was 9.1 years. Most mutation carriers reported
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Puerto Rico as the country of origin, whereas the others were
from the Dominican Republic.
Caribbean Hispanic GWAS Set
Among 2888 individuals in the confirmation set, 1473 (51.0%)
of the individualswereaffectedwithAD,and1918 (66.4%)were
women.Most affected individuals had LOAD, and theirmean
age at onsetwas 74.0 years (range, 30.0-105.0 years). The pro-
portion of APOE ε4 carriers (23.0%) was comparable to those
with EOAD family members.
Genome-wide Linkage Analysis of Families
Carrying the PSEN1 p.G206AMutation
For the purpose of gene discovery, we conducted genome-
wide linkage analyses of AD and age at onset using 5 multi-
plex families with variable age at onset. The linkage analysis
Table 1. Demographic and Clinical Characteristics of Sequenced Participants and FamilyMembersa
Characteristic
Genotyped
(n = 56 [5 Families])
Sequenced




Affected 21 (37.5) 26 (83.9) 1473 (51.0)
Unaffected 32 (57.1) 5 (16.1) 1408 (48.8)
Unknown 3 (5.4) 0 6 (0.2)
Sex, male:female 19:37 (33.9:66.1) 12:19 (38.7:61.3) 970:1918 (33.6:66.4)
Age at onset or age at last
examination, mean (SD), y
57.2 (7.0) 57.9 (9.9) 74.0 (10.0)
Educational level, mean (SD), y 10.0 (4.6) 9.1 (5.2) 5.7 (4.7)
APOE frequency
E4 23 (20.5) 19 (30.6) 1238 (23.0)
E3 85 (75.9) 43 (69.4) 3849 (71.5)
E2 4 (3.6) 0 (0.0) 293 (5.5)
Abbreviation: GWAS, genome-wide
association study.
a Data are presented as number
(percentage) of participants unless
otherwise indicated. The combined
GWAS data set has a total of 2324
unrelated individuals (2321 families
and 3 individuals whomarried into
the families).












































The bars represent logarithm of odds (LOD) scores from single-point linkage analysis, and points without the bar represent –log10 P values from association analysis.
Approximate locations for relevant genes as well as physical locations on chromosome 4 (chr4) are presented at the bottom of the figure.
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of AD identified the strongest linkage support for rs13478 at
4q35.1 (LOD score, 3.69), and 3 additional SNPs (rs1024026,
rs1983503, rs2036912) from the 6K linkagepanelwere sugges-
tive (Figure). This locus includedmultiple genes in linkagedis-
equilibrium, includingC4orf41, STOX2,MLF1IP, SORBS2, and
FAM149A. Our subsequent informatics analysis based on the
CANDIDalgorithm20 identified3topcandidategenes:SLC25A4,
SORBS2, andKIAA1430. On the other hand, the linkage analy-
sis of age at onset that adjusted for sex, AD status, and APOE
ε4didnot identifyanySNPswith suggestiveor significantLOD
scores. An additionalmodel that included the presence or ab-
sence of thePSEN1p.G206Avariant in addition to sex, AD sta-
tus, and APOE ε4 yielded the highest LOD score of 0.75.
Targeted and Genome-wide Association Analysis
of PSEN1 p.G206A Carriers
Using 31PSEN1p.G206Amutation carriers,weperformed tar-
geted association analysis with the genes located under the
linkage peak at 4q35.1. In addition, we performed genome-
wideassociationanalysisofageatonset in therestof theexome
by applying a multivariate linear mixed model that adjusted
for sex,AD status,APOE ε4, andkinship coefficient.21 The lin-
earmixedmodel was applied to take into account 5 individu-
alswhowere related toothers included in theexomesequenc-
ingexperiment.Under the linkagepeak, several SNPsprovided
modest support for association with age at onset, but we fo-
cused on SORBS2 because of the strong support from the in-
formatics analysis and the linkage analysis. The effect of the
minor allele of rs13130022 inSORBS2wasassociatedwithade-
lay in age at onset by 11.1 years (see β coefficients in Table 2).
In the remaining exome, the strongest signal for age at onset
wasobservedat rs906815 inNPHP1at2q13 (P = 4.51×10−6). Spe-
cifically, individuals carrying the rareAallele for rs906815had
an age at onset approximately 11.7 years earlier for having one
copy of theA allele comparedwith thosewhodonot, thereby
leading to nearly a difference of 2 decades in age at onset (ie,
44 vs 64.17). In addition, the effect variants in SNX25 and
SH3RF3wereassociatedwith adelay in ageat onset by8.8 and
9.3 years, respectively, whereas the effect variant in PDLIM3
was associated with an earlier onset by 12 years. In addition,
rs696662 on 1p13.1 (P = 6.8 × 10−6), rs906815 on 2q13 (P = 4.5 ×
10−6), and rs3026115 on 17p13.2 (P = 7.8 × 10−5) had SNPs with
strong support for allelic association.
To be conservative, we performed one additional analy-
sis of age at onset of AD inwhichwe restricted the analysis to
affected individuals only.This analysis yieldedcomparable re-
sults as the survival analysis approach. For example, rs906815
inNPHP1hadaPvalueof4.13× 10−6, andother SNPs thatwere
significant in theearlier analysis remained statistically signifi-
cant, but the P values were somewhat weakened (eTable 2 in
the Supplement).
Replication in IndividualsWith LOAD: Genewise Analysis
Todeterminewhether thevariantsdiscovered fromthePSEN1
p.G206Acarrier familieswere likely tobeassociatedwithvaria-
tion in age at onset in LOAD, we first conducted genewise as-
sociation analysis using FAMSKAT22 because the Hispanic
GWAS data sets did not include the variants identified from
exome sequencing of the discovery set. We confirmed that
SNX25 (P = 1.26 × 10−15), PDLIM3 (P = 1.17 × 10−11), SORBS2
(P = 3.8 × 10−6), NPHP1 (P = 5.47 × 10−5), and SH3RF3 (P = 2.7
× 10−11) were associated with age at onset in Caribbean His-
panicswithLOAD, further supporting that these genesmaybe
involved functionally in alteringphenotypic expression inAD.
Replication in IndividualsWith LOAD: SNP-wise Analysis
To further explore whether allelic association persists within
those candidate genes in LOAD, we examined SNPs from the
3GWASdata sets of CaribbeanHispanic ancestry, focusing on
theSNPs in the same linkagedisequilibriumblock as theorigi-
naldiscoveryvariants.BecausetheGWASdatasetsdidnothave
genotypes formanyof thevariantsdiscovered fromexomese-
Table 2. Summary of Linkage, Allelic, and Genewise Association Analyses in EOAD and LOAD
Gene
EOAD Exome Sequencing–Allelic Association LOAD-GWAS
SNP Location, bp β P Value No. of SNPsa P Value for Genewise Analysis
Linkage Signal
4q35
STOX2 rs28411264 184 908 447 13.01 .03851 12 .83
ENPP6 rs13147555 185 074 686 −6.06 .03024 28 .002
MLF1IP rs1401359 185 640 216 −5.11 .09064 58 7.22 × 10-6
SNX25 rs11730401 186 268 129 8.75 .0004 17 1.26 × 10−15
PDLIM3 rs28522047 186 446 018 −11.97 .1218 13 1.17 × 10−11
SORBS2 rs13130022 186 678 161 11.11 .0013 143 3.80 × 10−6
FAM149A rs2276920 187 078 938 7.11 .01671 14 .04
Association Signal
2q13
SH3RF3 rs6542814 109 928 460 9.30 .001 157 2.70 × 10−11
NPHP1 rs906815 110 942 496 −11.69 4.51 × 10−6 12 5.47 × 10−5
Abbreviations: bp, base pair; EOAD, early-onset Alzheimer disease; GWAS, genome-wide association study; LOAD, late-onset Alzheimer disease;
SNP, single-nucleotide polymorphism.
a The SNPwith the strongest P value from the exome sequencing experiment is given.
Genetic Variants of Alzheimer Disease Onset Original Investigation Research
jamaneurology.com (Reprinted) JAMANeurology Published online July 27, 2015 E5
Downloaded From: http://archneur.jamanetwork.com/ by a Columbia University User  on 08/01/2015
Copyright 2015 American Medical Association. All rights reserved.
quencing, we performed imputation using PLINK24 and then
used both genotype and imputed SNPs for allelic association.
We limited theuse of imputed SNPs to thosewith an informa-
tionscoregreater than0.8byPLINKanalysis.As shownineFig-
ure 3 in the Supplement, pairwise D′ values across the chro-
mosomal regions encompassing the discovery variants in
candidate loci were high and were comparable across the 3
GWAS data sets.
Table 3 indicates thatmultiple genotyped or imputeddata
in the candidate genes were associated with age at onset in
LOAD. In this confirmationanalysis, 14SNPs inSNX25wereas-
sociated with age at onset at P < .05, and variants were associ-
atedwith 1 to 6 years of difference in age at onset in LOAD. For
PDLIM3, 3 SNPs were associatedwith variation in age at onset
andwereassociatedwithadifferenceof2.6 to3.6years inmean
age at onset. For SORBS2, 11 of 1246 SNPs or indels flanking the
originaldiscoveryvariantweresignificantlyassociatedwithage
atonsetofLOADatP < .05,andthevariantswereassociatedwith
1 to 4.6 years ofmean agedifference in onset. It is of interest to
note that, for SORBS2, the same allele was associatedwith age
atonset inall 3GWASdata sets, and theallele frequency for the
associated SNP was consistent across data sets, ranging from
0.032 to0.222withamedianof0.194.ForSH3RF3, 5 SNPswere
associatedwith age at onset at P < .05 in LOAD, and the differ-
ence inmeanageatonset rangedfrom1to2.9years.ForNPHP1,
only one SNPwas associated with age at onset.
Table4summarizesreanalysisof the10SNPsfromthe2can-
didate genes (SORBS2 and SH3RF3) using genotypeddata. The
rationale forgenotyping thesesubsetsofSNPs fromTable3was
that the informationscore for the imputedSNPs inthose2genes
did not reach the satisfactory quality control threshold of 0.8
accordingtoourPLINKanalysis; thus, theresults fromthemeta-
analysis based on smaller data sets are likely to be less reliable
whencomparedwithotherSNPswithhigh informationscores.
Whengenotypeddatawereused, rs72939527 inSH3RF3hadthe
strongest support for allelic association (P = .007). The T allele
in rs72939527 was associated with a 2.7-year earlier age at on-
set comparedwith the reference allele,whereas other variants
did not reach statistical significance (P = .22-.47).
Discussion
We focused on founder mutation PSEN1 p.G206A with high
penetranceto identifygeneticmodifiersofageatonsetofEOAD
andLOADandreport thatvariants inSNX25,PDLIM3,SORBS2,
SH3RF3, andNPHP1may contribute to variation in age at on-
set in EOAD and LOAD. This study of a founder mutation al-
lows identification of a second locus that may alter the effect
of thehighlypenetrant, nonsynonymousPSEN1p.G206Avari-
ant. This approachovercomes someof the limitations that are
common instudies thatexaminegene-gene interaction invari-
ants withmodest to weak effect sizes. Furthermore, changes
inageatonsetbygenotypeamongPSEN1p.G206Acarrier fami-
lies ranged from 10 to 20 years, whereas those among indi-
vidualswithLOADranged from1 to6.2years. This finding sug-
gests that the difference in age at onset by genotype is likely
to be smaller in noncarriers compared with G206A carriers.
Familial EOAD is caused by mutations in 3 genes: APP,
PSEN1, andPSEN2.25-28 Support clearlyexists for geneticmodi-
fiers because age at onset varies widely for carriers of APP,
PSEN2, and PSEN1. To date, only a few studies3,4,11 have re-
portedmodifiers. Investigatorshave attributedobservedvari-
able age at onset inPSEN2 to theAPOE ε4 allele.3,4 ForPSEN1,
Vélez and colleagues11 conducted a pooling- and bootstrap-
basedGWASto identifymultiplemodifiers.Among those, they
observed that rs10173717 in NPHP1 may alter age at onset in
PSEN1p.Glu280Ala carriers. However, rs10173717 reported by
Vélez et al11was located40.5kilobases (kb) away fromourown
discovery signal rs906815and76.1kbaway fromourGWASsig-
nal rs17842680. The authors did not report the difference in
age at onset by genotype.
In this study, 5 promising genetic modifiers were identi-
fied among familiesmultiply affectedbyAD: SNX25, PDLIM3,
SORBS2, SH3RF3, and NPHP1. SNX25 has been implicated in
regulating endosome sorting and signaling.29,30 Given its po-
tential role in regulatingmembraneprotein trafficking excess
levelsof amyloidβ in individualswith thePSEN1p.G206Avari-
ant, this genemaybe abiologically relevantmodifier. This hy-
pothesis is further supported by an earlier report31 that found
that SNX3, a gene in the same family,was associatedwithAD,
and SNX3 regulates and interacts with the retromer mem-
brane. PDLIM3 is reported to be associatedwith diabetes and
cardiomyopathy.32Althoughtherehavebeenreportsof insulin-
related genes, little is known about the role of PDLIM3 in de-
mentia todate. Interestingly,however, thePDZdomain is regu-
latedbySNX27 retromerprotein, anddeficiencies in retromers
have been associated with AD.33
The remaining 3 candidate genes encode proteins with a
functional domain, SH3. These evolutionarily conserved do-
mains are defined by sequence homology and are involved in
protein-protein interaction.34,35 SH3 domains are ubiquitous
intracellular protein modules; structural and functional
studies34-37 reveal how they interactwith their praline-rich li-
gands to promote the formation of specific protein aggre-
gates.TheSH3domain is related to theWWandPTBdomains37
and may interact with APP to modulate the degradation of
APP.35 The SORBS2 gene—an SH3-binding domain gene lo-
cated in 4q35.1 under the strongest linkage peak—transcribes
a brain-specific splice variant knownasnARGBP2.38 This vari-
antwas reported to influence the integrityof f-actin in theden-
dritic spinesofneurons.Cestra andcolleagues39 observed that
overexpression of nARGB2 in mice caused aggregation of f-
actin bundles in dendritic spines and may influence pheno-
typic expression. Because alterationof synaptic shapemaybe
associated with the biological progression of AD, variants in
SORBS2 may influence variation in age at onset by affecting
dendritic spinemorphologic and subsequentneurodegenera-
tive processes.
SH3RF3 is an important paralog of SORBS2. Becausepara-
logs arise from gene duplicationwithin the same species and
we foundallelic associationbetweenage at onset and SORBS2
as well as SH3RF3, SH3RF3 is a biologically plausible gene. In
the present data set, the rare homozygous genotype carriers
hadageatonset approximately20yearsearlier than thosewith
thewild-typehomozygousgenotypeunder themodel that ad-
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justed for sex,AD,APOE ε4, andkinship coefficient. These re-
sults suggest that some individualsharbor avariant inSH3RF3
thatmaymodify the effect of thePSEN1p.G206Amutationon
thedisease phenotype.Wenote that the SH3domain is found
in proteins of signaling pathways regulating the cytoskel-
eton. They also regulate the activity state of adaptor proteins
Table 3. Meta-analysis in Late-Onset Alzheimer Disease and the Difference inMean Age at Onset by Genotype Among Caribbean Hispanics
SNP Location, bp (HG19) A1a A2a Freq1a z Score P Value Directionb S1c S2c S3c Differenced
SNX25(4q35)
rs72706074 186 135 900 G A 0.072 2.07 .03821 +−+ I I I 1.2
rs72706075 186 136 511 C A 0.071 2.07 .03847 +−+ I I I 1.0
rs111645866 186 137 102 A C 0.071 2.07 .03847 +−+ I I I 1.0
rs72708003 186 143 673 T C 0.043 −2.40 .01634 −−− I I I −0.4
rs73873407 186 157 838 C T 0.019 −2.25 .02472 −−− I I I −6.2
rs73873412 186 167 895 G C 0.035 −2.42 .01538 ?−− I I −2.1
rs73873414 186 169 190 C A 0.035 −2.42 .01538 ?−− I I −2.1
rs73873415 186 171 421 T C 0.035 −2.42 .01538 ?−− I I −2.2
rs73873416 186 174 202 G A 0.034 −2.15 .03193 ?−− I I −2.1
rs10028004 186 177 378 G A 0.021 −2.06 .03991 −− ? I I −1.9
rs114698167 186 188 966 A C 0.048 2.09 .0368 ? ?+ I 1.8
rs72709980 186 207 628 A T 0.034 2.50 .01242 + ? ? I 2.8
rs140555723 186 241 606 G A 0.042 2.54 .01122 +++ I I I 2.7
rs1288550 186 259 737 T C 0.034 2.32 .02016 + ?+ I I 2.4
PDLIM3(4q35)
rs1385580 186 414 852 C T 0.036 −2.33 .02006 − ? ? I −3.4
rs143417134 186 415 740 T C 0.010 −2.34 .01955 − ? ? I −3.6
rs79071575 186 442 445 T C 0.027 −2.35 .01877 − ? ? I −2.6
SORBS2(4q35)
rs146271237 186 662 630 C T 0.043 −1.97 .04856 −−− I I I −4.6
rs10009306 186 663 793 C T 0.144 −2.17 .02995 −− ? G I −1.0
rs7679506 186 664 542 G T 0.153 −2.55 .01084 −−− G G G −1.0
rs1039239 186 667 811 A G 0.169 2.09 .03679 +++ I I I 0.2
rs13130022e 186 678 161 C T 0.213 1.90 .05763 +++ I I I 1.5
rs1021678 186 678 768 A G 0.204 2.30 .02155 +++ I I I 1.6
rs12715855 186 687 554 A C 0.203 2.19 .02827 +++ I I I 1.6
186687667 186 687 667 TCA T 0.204 2.30 .02155 +++ I I I 1.6
186687668 186 687 668 CACAT C 0.203 2.44 .01451 +++ I I I 1.7
rs1039236 186 688 918 T C 0.203 2.19 .02827 +++ I I I 1.6
rs1039235 186 690 013 A T 0.203 2.44 .01451 +++ I I I 1.7
186691125 186 691 125 G GC 0.202 2.34 .0193 +++ I I I 1.7
SH3RF3(2q13)
rs72939527 109 917 895 T C 0.012 2.18 .0295 ?++ I I 2.9
rs6542814e 109 928 460 .001 1.1
rs11679797 109 973 646 G T 0.026 1.99 .0462 ?+ ? I 1.1
rs13013000 109 982 224 T G 0.034 2.16 .0307 ?+ ? I 0.8
rs11674377 109 984 093 A G 0.034 2.16 .0307 ?+ ? I 1.1
rs113309962 109 987 615 T C 0.011 −2.37 .0179 − ? ? I …
NPHP1(2q13)
rs17842680 110 906 930 G A 0.041 1.97 .04942 +++ I I I 0.9
rs906815e 110 942 496 A G 0.282 0.31 .7547 −++ I G G −0.9
Abbreviations: A1, allele 1; A2, allele 2; bp, base pair; Freq1, frequency of allele 1;
G, genotype; HG19, human genome assembly 19; I, imputed; S1, GWAS dataset
1; S2, GWAS dataset 2; S3, GWAS dataset 3; SNP, single-nucleotide
polymorphism.
a Minor allele and its frequency.
bDirection of the β coefficient in 3 Hispanic genome-wide association data sets;
plus sign indicates age at onset increases with dosage of allele; minus sign, age
at onset decreases; and questionmark, not computed because quality of
imputation is poor.
c I and G in each Hispanic genome-wide data set, where S1 represents dataset 1,
S2, dataset 2, and S3 dataset 3. Imputed SNPs with an information score
greater than 0.8 by PLINK analysis were used; otherwise, imputed SNPs were
dropped, representing blank cells.
dDifference in mean age by genotype. When available, mean ages at onset of 2
homozygotes were used to compute the difference in mean onset. When a
homozygous rare variant was absent, mean age at onset of heterozygous
genotype was used.
e The SNPs from the discovery.
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(whichmediate specificprotein-protein interactions thatdrive
the formation of protein complexes) and other tyrosine ki-
nases (which transfer a phosphate group from adenosine tri-
phosphate to a protein in a cell, thereby functioning as an on-
and-off switch). Thus, it is plausible that this gene may be
involved in variable gene expression of related genes, which
in turn modify the age at onset of disease.
NPHP1, another SH3 domain gene, encodes a nephrocys-
tin-1 protein that may influence cell division and cell signal-
ing localized tomicrotubule-based structures.40This genehas
beenreported tobeassociatedwith retinitispigmentosa,neph-
ronophthisis, and neurodegeneration with brain iron accu-
mulation 1. This disease is associated with dementia as part
of the phenotypic spectrum, supporting biological relevance
of this gene in the neurodegenerative process.
This study has some limitations. Age at onset of AD phe-
notype is inherently difficult to measure accurately because
it is difficult to detect prodromal symptoms unless each indi-
vidual is followed up longitudinally from preclinical stage to
development of AD using sensitive biomarkers. Thus, re-
ported age at onset is an approximation. In addition, the ge-
neticvariants identified fromthis studymaybe relatively com-
mon in Caribbean Hispanics but not in the general US
populations.Thus, the identifiedvariants themselvesmayhave
limited value in other ethnic cohorts. However, our earlier
studies41-43 have found that when 2 cohorts of different eth-
nicity are studied, the same set of genes tends to be impli-
cated, but the effect size associated with each variant differs
somewhat. For example, the effect size for each SNP vary
among Caribbean Hispanics, African Americans, and
whites41,42; however, all 3 ethnic groups had SNPs that were
significantly associated with AD within the gene. Similarly,
SNPs in ABCA7 were associated with AD in African Ameri-
cans and whites, but the effect sizes differed.43
Conclusions
This studyof carriersof thePSEN1p.G206Amutationhas iden-
tified variants in SNX25, PDLIM3, and a family of SH3 domain
genes (SORBS2, SH3RF3, NPHP1) that may modify age at on-
set of EOAD. Furthermore, variants in SORBS2 consistently
were associated with delayed onset in EOAD and LOAD, al-
though lessprofoundly so inLOAD.On theotherhand, thedis-
coveryvariantandflankingvariants inSH3RF3andNPHP1were
significantly associated with EOAD, but their effect size was
modestwith LOAD.Onepossible explanation for lack of asso-
ciation in the present data set may be that the effect size for
SH3RF3 and NPHP1 may be relatively modest, and a larger
studymaybeneededtodetectsignificantassociation.Thepres-
ent findings are worthy of further investigation to under-
stand the pathobiology of AD.
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